After almost a year of policy disputes, staff turnover and complaints about management, Food and Drug Administration Commissioner Marty Makary resigned under pressure earlier this month. His successor will need to restore order at an agency in turmoil.
The White House can hardly be blamed for wanting a steady hand at the FDA ahead of midterm elections. Kyle Diamantas, the official selected as acting commissioner, has been described as someone who “radiates normal.” That’s a start — but reforming the FDA will require a more ambitious reset.
Many of the agency’s current challenges began with DOGE. Before Makary’s first day ...